Dysfunkcjonalny układ renina-angiotensyna we wstrząsie septycznym (MANTRA)
Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
This study will determine whether normalization of renin-angiotensin-aldosterone system (RAAS) signaling in sepsis occurs more rapidly with treatment with Angiotensin II compared with conventional vasopressors. Trial samples will be used to identify the best RAAS biomarker predictor of treatment response via in-depth longitudinal analysis of RAAS component and to determine the extent and mechanisms of Angiotensin II impact on innate immune function during sepsis. Successful accomplishment of our aims will provide the capability to improve endotyping of septic patients by establishing the most precise and robust measurement of renin (and RAAS dysfunction). This work will improve staging and clinical precision and will facilitate the criteria for therapeutic development of targets in septic shock.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Faza 4
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Ashish Khanna, MD
- Numer telefonu: 513-658-5866
- E-mail: ashish.khanna@wfusm.edu
Kopia zapasowa kontaktu do badania
- Nazwa: Lynnette Harris, RN
- Numer telefonu: 336-716-8791
- E-mail: lynnette.harris@advocatehealth.org
Lokalizacje studiów
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02114
- Massachusetts General Hospital-Harvard
-
Kontakt:
- Michael R Filbin, MD, MS
- E-mail: mfilbin@mgh.harvard.edu
-
Kontakt:
- Daniel E Leisman, MD
- E-mail: dleisman@mgh.harvard.edu
-
Główny śledczy:
- Michael R Filbin, MD, MS
-
Główny śledczy:
- Daniel E Leisman, MD
-
Pod-śledczy:
- Marcia Goldberg, MD
-
Pod-śledczy:
- Kathryn Hibbert, MD
-
-
North Carolina
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Atrium Health Wake Forest Baptist
-
Kontakt:
- Lynnette C Harris, BSN
- Numer telefonu: 336-716-8791
- E-mail: lcharris@wakehealth.edu
-
Kontakt:
- Ashish Khanna, MD
- Numer telefonu: 513-658-5866
- E-mail: akhanna@wakehealth.edu
-
Główny śledczy:
- Ashish Khanna, MD
-
Pod-śledczy:
- Christopher Schaich, PhD
-
Pod-śledczy:
- Daniel C Files, MD
-
Główny śledczy:
- Mark Chappell, PhD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- The presence of septic shock, defined by sepsis-3 criteria: 1-adult patients (18 years or older) with septic shock, defined by SEPSIS-3 criteria: a) suspected or known infection, b) hypotension requiring vasopressors, and c) lactate >2mmol/L 2-receiving either norepinephrine or phenylephrine with or without additional vasopressor support 3- total norepinephrine equivalent dose (NED) ≥0.1 mcg/kg/min and ≤0.5 mcg/kg/min, to maintain a MAP of at least 65 mmHg, is required for randomization 4-ability to consent and randomize within 24 hrs of first reaching NED threshold and within 48 hrs of hospital arrival
Exclusion Criteria:
- Age <18 years
- Prisoners
- Pregnant women
- Patients for whom urgent surgery is anticipated
- Leukocyte count <1,000 cells/μL
- Absolute monocyte count <200 cells/μL
- Bone marrow transplant within the past 30 days
- Patients that will be withdrawing aggressive resuscitation, including withdraw of vasopressor support
- transfer from outside ICU
- history of liver cirrhosis with Child-Pugh score ≥6
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Angiotensin II
Continuous infusion of Angiotensin II for up to 48 hours |
randomized to receive Angiotensin II continuous infusion for up to 48 hours |
|
Aktywny komparator: Norepinephrine
Continuous infusion of Norepinephrine for up to 48 hours |
randomized to receive Norepinephrine continuous infusion for up to 48 hours |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Mean Renin Level - Hour 24
Ramy czasowe: Hour 24
|
Mean plasma renin level (PRA) as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock. |
Hour 24
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Norepinephrine Equivalent Dose Requirement (NEE)
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
NEE indicates severity of shock and need for vasopressors to support blood pressure. Normal range is 0.0-1.0 mcg/kg/min. Levels above normal indicate shock and need for vasopressors. The higher the level the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Number of Days Without Renal Replacement Therapy
Ramy czasowe: Day 28
|
Number of days without renal replacement therapy |
Day 28
|
|
Number of Days of Vasopressor Use
Ramy czasowe: Day 28
|
Number of days without vasopressor use |
Day 28
|
|
Number of Days Without Mechanical Ventilation
Ramy czasowe: Day 28
|
Number of days without invasive mechanical ventilation |
Day 28
|
|
Number of Hours Vasopressor Free
Ramy czasowe: Hour 72
|
Number of hours without requiring vasopressors during first 72 hours after randomization |
Hour 72
|
|
Number of Hours Alive
Ramy czasowe: Hour 72
|
Number of hours alive during first 72 hours after randomization |
Hour 72
|
|
Number of Days Alive
Ramy czasowe: Day 28
|
Number of days alive |
Day 28
|
|
Mean Renin Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 48, Hour 72
|
Mean renin level as a measure of renin-angiotensin-aldosterone system restoration. Normal levels of active renin <1.1 pM (40 pg/mL). A level higher than normal can indicate level of shock. |
Baseline, Hour 3, Hour 12, Hour 48, Hour 72
|
|
Sequential Organ Failure Assessment (SOFA) Score
Ramy czasowe: Baseline, Hour 24, Hour 48
|
SOFA score indicates the number and severity of failed organs and provides prognostic information on in-hospital survival in patients with severe sepsis and septic shock. Score above 0 indicates organ failure. The higher the score the more failed organs and degree of organ failure. |
Baseline, Hour 24, Hour 48
|
|
APACHE-II Score
Ramy czasowe: Baseline, Hour 24, Hour 48
|
APACHE-II score assesses severity of illness in critically ill patients and indicates risk of mortality. Score range 0-10 low risk of mortality, 11-20 moderate risk, 21-30 high risk, 31 or above very high risk. |
Baseline, Hour 24, Hour 48
|
|
Lactate Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
Lactate is an indicator of sepsis severity. Levels 2.3-20 mmol/L indicate sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Kidney Disease Improving Global Outcomes (KDIGO) Stage
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Participant stage of acute kidney injury will be determined as follows Stage 1: Increase in serum creatinine ≥ 0.3 mg/dL in 48 hours or 1.5 to 1.9 multiplied by baseline (in 7 days); Stage 2: 2.0 to 2.9 multiplied by baseline serum creatinine; Stage 3: 3.0 or more multiplied by baseline; increase in serum creatinine ≥ 4.0 mg/dL; or beginning of renal replacement therapy regardless of a previous KDIGO stage. Higher stage indicates higher severity of renal failure. |
Baseline, Hour 24, Hour 48
|
|
Creatinine Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Creatinine level is an indicator of renal disease severity. Normal range for women 0.7-1.3 mg/dL, men 0.6-1.1 mg/dL. Levels higher than normal indicate renal disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
BUN Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
BUN level is an indicator of renal disease severity. Levels above 24 mg/dL indicate renal disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Bicarbonate Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Bicarbonate level is an indicator of acid base disturbance severity. Normal range is 22-29 mEq/L. Levels above or below the normal range indicate acid base disturbance. The higher the score the more severe. |
Baseline, Hour 24, Hour 48
|
|
Number of Participants with Acute Respiratory Distress Syndrome (ARDS)
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Number of participants with ARDS |
Baseline, Hour 24, Hour 48
|
|
SpO2/FiO2 Ratio Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
SpO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 315-235, moderate severity 148-235, severe <148. |
Baseline, Hour 24, Hour 48
|
|
PaO2/FiO2 Ratio Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
PaO2/FiO2 ratio level is an indicator of lung injury severity. Mild severity 201-300 mmHg; moderate severity 101-200 mmHg, severe ≤ 100 mmHg. |
Baseline, Hour 24, Hour 48
|
|
Serum Aspartate Aminotransferases Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Serum aspartate aminotransferases level is an indicator of liver injury severity. Normal range 8-48 U/L. Levels above normal indicate livery injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Alanine Aminotransferases Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Alanine aminotransferases level is indicator of liver injury severity. Normal range 7-55 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Alkaline Phosphatase Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Alkaline phosphatase level is an indicator of liver injury severity. Normal range 40-129 U/L. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Bilirubin Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Bilirubin level is an indicator of liver injury severity. Normal range 0.1-1.2 mg/dL. Levels higher than normal indicate liver injury. The higher the liver the more severe. |
Baseline, Hour 24, Hour 48
|
|
Albumin Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Albumin level is an indicator of liver injury severity. Normal range 3.5-5.0 g/dL. Levels higher than normal indicate liver injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Troponin I Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Troponin I level is an indicator of cardiac myocyte injury. Normal range 0-0.04 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Troponin T Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Troponin T level is an indicator of cardiac myocyte injury. Normal range 0-0.01 ng/mL. Levels higher than normal indicate cardiac myocyte injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Neutrophil Gelatinase-Associated Lipocalin Serum Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Neutrophil gelatinase-associated lipocalin serum level indicates risk of kidney injury. Normal serum level is <10 mcg/L. Levels higher than normal indicate risk of kidney injury. |
Baseline, Hour 24, Hour 48
|
|
Neutrophil Gelatinase-Associated Lipocalin Urine Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Neutrophil gelatinase-associated lipocalin urine level indicates risk of kidney injury. Normal urine level is ≤50 ng/ml. Risk of kidney disease: Low risk 51-149 ng/ml, moderate risk 150-299 ng/ml, and high risk ≥300 ng/ml. |
Baseline, Hour 24, Hour 48
|
|
Kidney Injury Molecule-I Urine Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Kidney injury molecule-I urine level is used to detect kidney injury. Normal level is <1 ng/ml. Levels higher than normal indicate ischemic kidney injury. |
Baseline, Hour 24, Hour 48
|
|
Kidney Injury Molecule-I Blood Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Kidney injury molecule-I blood level is used to detect kidney injury. Normal levels 0.42-2.0 ng/ml. Levels higher than normal indicate kidney injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Soluble Receptor for Advanced Glycation End Product Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Soluble receptor for advanced glycation end product level is a marker of aging, hypertension and diabetes. Normal range is 647-1248 pg/ml. Levels higher than normal indicate risk for hypertension and diabetes. |
Baseline, Hour 24, Hour 48
|
|
Angiopoietin-2 Level
Ramy czasowe: Baseline, Hour 24, Hour 48, Hour 72
|
Angiopoietin-2 level is a marker of inflammation. Normal range is 1434-4141 pg/mL. Levels higher than normal indicate inflammation. |
Baseline, Hour 24, Hour 48, Hour 72
|
|
Syndecan-1 Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Syndecan-1 level is a marker of disease severity in critically ill patients. Levels >20ng/ml indicate severe disease. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Protein C Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Protein C level is an indicator of inflammation and thrombotic state. Normal level is <8 mg/L. Levels higher than normal indicate inflammation and thrombotic state. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
Neuron-Specific Enolase Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
Neuron-specific enolase level is an indicator of brain injury. Normal range is 16-17 ug/L. Levels higher than normal indicate brain injury. The higher the level the more severe. |
Baseline, Hour 24, Hour 48
|
|
S-100β Level
Ramy czasowe: Baseline, Hour 24, Hour 48
|
S-100β level is indicator of brain injury. Normal range is 0.02-0.05 μg/dL. Levels higher than normal indicate brain injury. The higher the number the more severe. |
Baseline, Hour 24, Hour 48
|
|
TNFα Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
TNFα level is an indicator of systemic inflammation. Normal levels are 75 +/- 15 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
sTNFR1 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
sTNFR1 level is an indicator of systemic inflammation. Normal levels are <2.4 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-6 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-6 level is an indicator of systemic inflammation. Normal range is 0-43.5 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
sIL-6R Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
sIL-6R level is an indicator of systemic inflammation. Normal range is 14-46 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-8 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-8 level is an indicator of systemic inflammation. Normal range is 0-66.1 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-1β Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-1β level is an indicator of systemic inflammation. Normal range is 0.5-12 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Interferon Gamma Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IFN-ɣ level is an indicator of systemic inflammation. Normal range is 0-8.6 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL12p70 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL12p70 level is an indicator of systemic inflammation. Normal range is 0-1.9 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-17 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-17 level is an indicator of systemic inflammation. Normal range is 0-1.4 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
MIP1-alpha Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
MIP1-αlpha level is an indicator of systemic inflammation. Normal range is 0-208 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
MIP1-beta Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
MIP1-beta level is an indicator of systemic inflammation. Normal range is 59-647 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IP-10 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IP-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-10 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-10 level is an indicator of systemic inflammation. Normal range is 4.8-9.8 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-1RA Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-1RA level is an indicator of systemic inflammation. Normal range is 100-300 ng/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
IL-12p40 Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
IL-12p40 level is an indicator of systemic inflammation. Normal range is 0.064-1000 pg/ml. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
C reactive protein (CRP) Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
CRP level is an indicator of systemic inflammation. Normal range is 0-10 mg/dl. Levels higher than normal indicate inflammation. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Procalcitonin Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Procalcitonin level is an indicator of systemic inflammation. Levels >0.25 mg/ml indicate inflammation and infection. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Platelet Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Platelet level is an indicator of systemic inflammation and thrombocytosis. Normal range is 150000-450000 platelets per microliter. Levels higher than normal indicate inflammation and thrombocytosis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Neutrophil Count Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute neutrophil count level is an indicator of inflammation and infection/sepsis. Normal range is 2500-7000 neutrophils per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Granulocyte Count Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute granulocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1500-8500 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Absolute Lymphocytes Count Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Absolute lymphocyte count level is an indicator of inflammation and infection/sepsis. Normal range is 1000-4800 granulocytes per microliter. Levels higher than normal indicate inflammation, infection/sepsis. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Neutrophil-Lymphocyte Ratio Level
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
Neutrophil-lymphocyte ratio level is an indicator of inflammation and infection/sepsis or marrow malignancy. Normal range is 1-2. Levels higher than normal indicate inflammation, infection/sepsis, marrow malignancy. The higher the score the more severe. |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48
|
|
Angiotensin (1-7)
Ramy czasowe: Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
Angiotensin (1-7) level as a measure of the renin-angiotensin-aldosterone system |
Baseline, Hour 3, Hour 12, Hour 24, Hour 48, Hour 72
|
|
Plasma renin activity
Ramy czasowe: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Prorenin
Ramy czasowe: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Soluble prorenin receptor (sPRR)
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Aldosterone
Ramy czasowe: baseline, hour 3, hour 12, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48
|
|
Intact Aogen
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
ANG II
Ramy czasowe: baseline, hour 3, hour 12, hour 24, hour 48, hour 72
|
levels at indicated timepoints |
baseline, hour 3, hour 12, hour 24, hour 48, hour 72
|
|
Angiotensin-converting enzyme (ACE)
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Angiotensin-converting enzyme-2 (ACE2)
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Dipeptidyl peptidase 3 (DPP3)
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
RNA Paxgene Bulk (Bulk RNA sequencing)
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
|
Whole blood cryopreserved (scRNAsesq)
Ramy czasowe: baseline, hour 24, hour 48
|
levels at indicated timepoints |
baseline, hour 24, hour 48
|
Inne miary wyników
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Patients with New Deep Venous Thrombosis
Ramy czasowe: Day 7, Day 28
|
Number of patients with development of new deep venous thrombosis |
Day 7, Day 28
|
|
Patients with New Pulmonary Embolism
Ramy czasowe: Day 7, Day 28
|
Number of patients with development of new pulmonary embolism |
Day 7, Day 28
|
|
Patients with New-Onset Atrial Fibrillation
Ramy czasowe: Hour 72, day 28
|
Number of patients with new-onset atrial fibrillation |
Hour 72, day 28
|
|
Patients with New-Onset Ventricular Arrhythmias
Ramy czasowe: Hour 72, Day 7, Day 28
|
Number of patients with new-onset ventricular arrhythmias |
Hour 72, Day 7, Day 28
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Ashish Khanna, MD, Atrium Health Wake Forest Baptist
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Procesy patologiczne
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Infekcje
- Zespół ogólnoustrojowej reakcji zapalnej
- Zapalenie
- Zaszokować
- Stany patologiczne, oznaki i objawy
- Posocznica
- Choroby nerek
- Szok, septyczny
- Hormony
- Hormony, substytuty hormonów i antagoniści hormonów
- Hormony peptydowe
- Neuropeptydy
- Peptydy
- Aminokwasy, peptydy i białka
- Oligopeptydy
- Białka tkanek nerwowych
- Białka
- Organiczne chemikalia
- Węglowodory
- Węglowodory, cykliczne
- Czynniki biologiczne
- Węglowodory, aromatyczne
- Aminy
- Katechole
- Fenole
- Pochodne benzenu
- Alkohole
- Alkohole aminowe
- Etanolaminy
- Autakoidy
- Mediatory zapalne
- Biogeniczne monoaminy
- Biogeniczne aminy
- Katecholaminy
- Angiotensyny
- Norepinefryna
- Angiotensyna II
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- IRB00115287
- R01HL177834 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .